Key Details
Price
$127.65Last Dividend
$0.59Beta
0.13Events Calendar
Next earnings date:
Apr 17, 2025Recent quarterly earnings:
Jan 22, 2025Recent annual earnings:
Jan 22, 2025Next ex-dividend date:
N/ARecent ex-dividend date:
Jan 15, 2025Next split:
N/ARecent split:
Jan 02, 2013Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
In December, the ProShares S&P 500 Dividend Aristocrat ETF experienced its third worst monthly return, dropping by 7.69%. I will share three strategies that could potentially outperform the dividend aristocrat index over time. After monitoring these strategies for 42 months, two of them have shown a compound annual growth rate (CAGR) that is better than NOBL.
Lately, users of Zacks.com have been focusing on Abbott (ABT). This interest prompts a closer look at what the stock might offer.
Investors are hopeful about Abbott's strong performance in the Core Diagnostics sector. However, they are worried about the negative effects of foreign exchange rates.
Abbott (NYSE: ABT) has just announced its Q4 results, showing revenues slightly lower than expected while earnings matched analysts' predictions. The company generated $10.97 billion in revenue and earnings of $1.34 per share, which aligns with the adjusted estimates of $1.34 but falls short of the revenue forecast of $11.01 billion.
On January 22, Abbott Laboratories released its financial results for the fourth quarter of 2024, which received a mixed response from Wall Street. The company's revenue for the three months ending December 31, 2024, was approximately $10.97 billion, reflecting a 7.2% increase compared to the previous year, mainly due to strong sales in its Medical Devices division. Additionally, Abbott anticipates a revenue growth of 7.5% to 8.5% in 2025, with adjusted diluted earnings per share expected to be between $5.05 and $5.25, indicating significant year-over-year growth.
On Wednesday, Abbott Laboratories ABT announced that its sales for the fourth quarter reached $10.97 billion, which is a 7.2% increase compared to the same period last year. However, this figure fell short of the expected $11.01 billion.
As the new year begins, it's an ideal moment to invest in stocks that may enhance your portfolio for 2025 and beyond. The healthcare sector is a promising area to explore, offering a mix of growth and stability. You can find everything from innovative biotech companies to established pharmaceutical and medical device firms that provide popular drugs and dividends to their investors.
Tariff Day has put Canada and Mexico in a challenging position. With North American trade being highlighted, this could provide some relief for stocks that rely on supply chains in other regions and boost their performance.
U.S. stocks rose as trading came to a close, with the Nasdaq Composite increasing by about 250 points on Wednesday.
Abbott (ABT) reported quarterly earnings of $1.34 per share, matching the Zacks Consensus Estimate. This is an increase compared to earnings of $1.19 per share from the same period last year.
FAQ
- What is the primary business of Abbott Laboratories?
- What is the ticker symbol for Abbott Laboratories?
- Does Abbott Laboratories pay dividends?
- What sector is Abbott Laboratories in?
- What industry is Abbott Laboratories in?
- What country is Abbott Laboratories based in?
- When did Abbott Laboratories go public?
- Is Abbott Laboratories in the S&P 500?
- Is Abbott Laboratories in the NASDAQ 100?
- Is Abbott Laboratories in the Dow Jones?
- When was Abbott Laboratories's last earnings report?
- When does Abbott Laboratories report earnings?
- Should I buy Abbott Laboratories stock now?